The Value of Forced Expiratory Volume in 1 Second Decline in the Assessment of Chronic Obstructive Pulmonary Disease Progression
Forced expiratory volume in 1 second (FEV 1) declines normally with aging by approximately 30 mL/yr, but in susceptible smokers, the decline is greater (about 60 mL/yr), resulting in the development of chronic obstructive pulmonary disease (COPD). Smoking cessation usually restores the normal or nea...
Gespeichert in:
Veröffentlicht in: | The American journal of medicine 2006-10, Vol.119 (10), p.4-11 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Forced expiratory volume in 1 second (FEV
1) declines normally with aging by approximately 30 mL/yr, but in susceptible smokers, the decline is greater (about 60 mL/yr), resulting in the development of chronic obstructive pulmonary disease (COPD). Smoking cessation usually restores the normal or near-normal rate of FEV
1 decline, whereas intermittent quitting provides less benefit. Thus, smoking cessation is a critical component for the prevention of COPD progression. FEV
1 is central to the definition of COPD and classification of its severity. FEV
1 is a good predictor of exercise tolerance and correlates with survival and quality of life. More rapid FEV
1 decline is also predictive of morbidity, mortality, and hospitalization rates. Risk factors for accelerated decline in FEV
1, in addition to smoking, include frequent exacerbations, airways reactivity, and possibly chronic systemic inflammation. Genetic components of the decline in FEV
1 are being actively explored, but none has been extensively validated other than α
1-antitrypsin deficiency. To date, only smoking cessation has been definitively shown to be effective in reducing the rate of FEV
1 decline, but other therapeutic strategies are under active research. Consequently, FEV
1 and its change over time are important outcomes in COPD and valuable measures for the assessment of disease progression. |
---|---|
ISSN: | 0002-9343 1555-7162 |
DOI: | 10.1016/j.amjmed.2006.08.002 |